BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8616084)

  • 1. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin's lymphoma undergoing cytoreductive chemotherapy.
    Reisbach G; Kamp T; Welzl G; Geiz C; Abedinpour Fariborz ; Lodri A; Kaboth W; Dörmer P; Nerl C
    Br J Haematol; 1996 Mar; 92(4):907-12. PubMed ID: 8616084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia.
    Sallerfors B; Olofsson T
    Br J Haematol; 1991 Jul; 78(3):343-51. PubMed ID: 1714757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
    Kawano Y; Takaue Y; Saito S; Sato J; Shimizu T; Suzue T; Hirao A; Okamoto Y; Abe T; Watanabe T
    Blood; 1993 Feb; 81(3):856-60. PubMed ID: 7679001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum in bone marrow transplanted patients.
    Sallerfors B; Olofsson T; Lenhoff S
    Bone Marrow Transplant; 1991 Sep; 8(3):191-5. PubMed ID: 1720339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor, PIXY-321, stem cell factor, interleukin-3, and interleukin-7: receptor binding and effects on clonogenic proliferation in acute lymphoblastic leukemia.
    Drach D; Estrov Z; Zhao S; Drach J; Cork A; Collins D; Kantarjian H; Andreeff M
    Leuk Lymphoma; 1994 Dec; 16(1-2):79-88. PubMed ID: 7535143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum TNF-alpha, gamma-INF, G-CSF and GM-CSF levels in neutropenic children with acute leukemia treated with short-course, high-dose methylprednisolone.
    Tuncer AM; Hiçsönmez G; Gümrük F; Sayli T; Güler E; Cetin M; Okur H
    Leuk Res; 1996 Mar; 20(3):265-9. PubMed ID: 8637222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
    Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
    J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
    Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality.
    Presneill JJ; Waring PM; Layton JE; Maher DW; Cebon J; Harley NS; Wilson JW; Cade JF
    Crit Care Med; 2000 Jul; 28(7):2344-54. PubMed ID: 10921563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
    Bruserud O
    Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
    Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
    J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of continuous subcutaneous administration of a small dose of granulocyte colony stimulating factor (G-CSF) by the use of a portable infusion pump in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Furuya H; Wakayama T; Ohguni S; Yamauchi K; Tanaka J; Hatazoe T; Kato Y
    Int J Hematol; 1995 Apr; 61(3):123-9. PubMed ID: 7541257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis.
    Estrov Z; Talpaz M; Mavligit G; Pazdur R; Harris D; Greenberg SM; Kurzrock R
    Am J Med; 1995 Jun; 98(6):551-8. PubMed ID: 7539977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte and granulocyte-macrophage colony-stimulating factors, their receptors and interleukin-3 levels in newborns.
    Coşkun M; Kardelen F; Oygür N; Undar L; Savaş A; Yeğin O
    Turk J Pediatr; 1997; 39(3):295-301. PubMed ID: 9339107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous haemopoietic growth factors in neutropenia and infection.
    Cebon J; Layton JE; Maher D; Morstyn G
    Br J Haematol; 1994 Feb; 86(2):265-74. PubMed ID: 7515265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.